We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Eli Lilly’s rheumatoid arthritis treatment Olumiant (baricitinib) reduced mortality in COVID-19 patients by 71 percent in a small clinical trial led by Sweden’s Karolinska Institutet. Read More
Moderna announced this week that its coronavirus vaccine, mRNA-1273, appears to not only be more effective than Pfizer’s candidate but has significantly less stringent temperature requirements as well, likely making distribution and storage of the vaccine an easier, less daunting task. Read More
Inovio has launched the phase 2 portion of its phase 2/3 clinical trial evaluating INO-4800, a potential coronavirus vaccine funded by the Department of Defense (DoD). Read More
Hacker groups in Russia and North Korea have continue to wage cyberattacks against companies working on COVID-19 vaccines and treatments, Microsoft warned Monday, calling on governments to take action against them. Read More
A new survey shows one in five cancer patients are far less likely to participate in future clinical trials due to fear of COVID-19 exposure, raising the question of whether enrollment levels that have dropped precipitously since the beginning of the pandemic are likely to recover after the virus is controlled. Read More
Despite the FDA’s recent approval, international skepticism persists over the use of Gilead Sciences’ remdesivir for treating COVID-19 patients. Another prominent group, the European Society of Intensive Care Medicine, is now advising clinicians that the drug should not be routinely used for treating COVID-19 patients Read More
A small U.S. study found that the anti-depressant, fluvoxamine, may have potential as a treatment of COVID-19 patients with breathing problems. Read More
Moderna announced last week that it has seen an increased rate of COVID-19 cases across sites in its late-stage vaccine trial and, as a result, its first interim analysis will include significantly more coronavirus cases than anticipated. Read More
The Infectious Diseases Society of America (IDSA) said that it is conducting its own evaluation of the data that led to the FDA’s Emergency Use Authorization (EUA) for the 700-mg dose of Eli Lilly’s COVID-19 antibody treatment bamlanivimab. Read More